Home :: Kentucky Heart Foundation

The Kentucky Heart Foundation is a non-profit research institute dedicated to improving quality of life by reducing the devastating impact of cardiovascular disease in the tri-state area through research, education, prevention and early detection.

Click to Learn More
Education and screenings sponsored by the Kentucky Heart Foundation provide a platform for prevention and early detection of heart and vascular disease as well as early treatment. Education focuses on physicians, the public and staff.

Click to Learn More
Kentucky Heart Foundation focuses its research on introducing new and effective therapies to King’s Daughters Medical Center and to the region. By promoting research, we help answer clinical questions and optimize patient care today and into the future.

Click to Learn More

Latest News

Fri, March 12, 2010
Poster, essay contest winners announced
The Kentucky Heart Foundation is pleased to announce the winners of its "Why I love my heart" poster and essay contests, which were held in celebration of American Heart Month. Students were challenged to create posters (kindergarten through fifth grade) or essays (sixth through twelfth grade) illustrating the theme.

Wed, February 24, 2010
KDMC Offers Free Screening at Vanceburg
King’s Daughters Medical Center, in cooperation with the Kentucky Heart Foundation (KHF), is offering a free screening to detect PAD. The screening will begin at 8:30 a.m. March 5 at the Primary Plus Women’s Center, at the intersection of the AA Highway and Ky. Route 59 in Vanceburg, Ky.

Mon, February 22, 2010
Boyd and Greenup Counties Receive Grant to Tackle Childhood Obesity
Boyd and Greenup counties have been selected as one of only a handful of communities in the country to become part of Action Communities for Health, Innovation, and EnVironmental ChangE (ACHIEVE).

Recently Added Trials

TAXUS Liberte`

The TAXUS Liberte` Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberte`Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This study is designed to evaluate the optimal duration of dual antiplatelet therapy.

TRILOGY

This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed US/NSTEMI ACS population (that is, patients who are not managed with acute coronary revascularization).

OptiVol Care Pathway

To compare monthly versus quarterly review of CardiacCompass Trends with OptiVol for initiation of clinical action.

APPRAISE 2

To determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome (ACS).